Investors·2025-11-07 15:29Group 1 - Eli Lilly is competing with Novo Nordisk in the weight-loss drug market, with products like Zepbound and Mounjaro [2] - The White House has announced deals with both companies to reduce prices on weight-loss drugs and expand coverage under Medicare and Medicaid [2] - The weight-loss drug market is projected to reach $150 billion by 2035, according to Morgan Stanley [2] Group 2 - Eli Lilly's stock has seen a rise in relative strength rating to 77, indicating positive market performance [5] - The Dow Jones experienced a significant decline of nearly 400 points, influenced by sell-offs in stocks like Nvidia, Robinhood, and Tesla [5] - Eli Lilly has been included among 17 new stocks added to IBD's top stock screens, highlighting its potential as a strong investment [5]